Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Flourescein sodium 10% injection (10 x 5ml amps)	TA274 - Ranibizumab for treating diabetic macular oedema
Fludarabine injection	TA119 - Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia TA29 - Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fludarabine tablets	TA119 - Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia TA29 - Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Flumazenil injection
Flunarazine tablets		Not licensed in the UK. Licensed in Europe and Ireland - preventative management in primary headache.
Fluocinolone acetonide intravitreal implant (Illuvien®)	TA301 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy TA590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluorescein sodium Minims
Fluorouracil injection	TA212 - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer TA307 - Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy	For hospital use only
Flupentixol decanoate injection		Hospital only. APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion).
Fluphenazine decanoate injection		Hospital only. APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion).

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.